Method Meta-analysis
Lead Research Organisation:
UNIVERSITY COLLEGE LONDON
Department Name: UNLISTED
Abstract
Systematic reviews are a way of bringing together similar clinical trials. Meta-analysis is a way of putting results or data from these trials together to work out whether treatments work, and network meta-analysis helps us decide which treatments work best.
Working alongside trial teams, we are developing new and improved ways of planning and doing these systematic reviews and meta-analyses, so that we can find out which treatments are best for patients quickly and reliably. Sometimes, treatments work better in some patients than in others, so we are also collecting more detailed data and developing reliable methods to explore this. We are developing better statistical techniques for doing all types of meta-analysis and network meta-analysis. To help others to use our new methods of doing things, we are writing user-friendly software, preparing guidance, and giving tutorials and training courses.
Working alongside trial teams, we are developing new and improved ways of planning and doing these systematic reviews and meta-analyses, so that we can find out which treatments are best for patients quickly and reliably. Sometimes, treatments work better in some patients than in others, so we are also collecting more detailed data and developing reliable methods to explore this. We are developing better statistical techniques for doing all types of meta-analysis and network meta-analysis. To help others to use our new methods of doing things, we are writing user-friendly software, preparing guidance, and giving tutorials and training courses.
Technical Summary
Systematic review and meta-analysis are essential tools for rigorously evaluating the effects of therapies, particularly integrating our trial results with those of other groups, and informing the design of our trials. This programme develops the methodology underpinning systematic reviews and meta-analyses, applies it in high-quality reviews relevant to our trials, and disseminates it to the scientific community. Interaction between systematic reviewers, methodologists and trialists is fundamental to these endeavours.
We have particular experience and an international reputation in the conduct of large collaborative systematic reviews and meta-analyses based individual participant data (IPD). Over more than 20 years, these have influenced the treatment of patients globally, and moreover, the data have been used to investigate methodological issues and develop robust solutions. However, such IPD meta-analyses are time- and resource-intensive, so a key aim is to establish when they are most needed to answer clinical questions reliably. Conversely, if aggregate data approaches are to provide a robust and speedier alternative, we need to move beyond the current methods of doing these, in order to limit the inherent biases.
With some clinical areas moving rapidly, there can be multiple trials comparing different treatments to one or more standard. This means that there is sometimes little opportunity for direct comparisons, so we also need the most robust and timely methods for network meta-analysis. We refer to pairwise meta-analysis (directly comparing two treatments) as MA and network meta-analysis (directly and indirectly comparing many treatments) as NMA.
In this area, we benefit from the arrival of new senior staff in 2017, which has substantially broadened our expertise in statistical modelling for MA and NMA. Our future plans will continue to integrate this expertise into our ongoing programme of work. For example, we will develop and implement state-of-the-art methodology in MA and NMA of time-to-event outcomes based on individual participant data (IPD), informing overall and stratified treatment decisions, while allowing for complexities in the design of the component trials, heterogeneity between trials, and inconsistency between direct and indirect evidence.
Our overall philosophy is to use the simplest methods that can be shown to be valid (often by methodological comparison with more complex methods), and wherever possible to work prospectively and collaboratively to reduce bias, increase the timeliness of our reviews, and achieve greater impact.
Our research covers four priority areas:
1. Beyond standard systematic reviews – developing review methods that move beyond standard approaches and using them to perform high-quality and challenging reviews
2. Determining methods to assess which participants benefit most from treatments in pairwise and network meta-analysis
3. Choosing and building appropriate models for in pairwise and network meta-analysis
4. Guidance and tools to increase impact of our meta-analysis methods
We have particular experience and an international reputation in the conduct of large collaborative systematic reviews and meta-analyses based individual participant data (IPD). Over more than 20 years, these have influenced the treatment of patients globally, and moreover, the data have been used to investigate methodological issues and develop robust solutions. However, such IPD meta-analyses are time- and resource-intensive, so a key aim is to establish when they are most needed to answer clinical questions reliably. Conversely, if aggregate data approaches are to provide a robust and speedier alternative, we need to move beyond the current methods of doing these, in order to limit the inherent biases.
With some clinical areas moving rapidly, there can be multiple trials comparing different treatments to one or more standard. This means that there is sometimes little opportunity for direct comparisons, so we also need the most robust and timely methods for network meta-analysis. We refer to pairwise meta-analysis (directly comparing two treatments) as MA and network meta-analysis (directly and indirectly comparing many treatments) as NMA.
In this area, we benefit from the arrival of new senior staff in 2017, which has substantially broadened our expertise in statistical modelling for MA and NMA. Our future plans will continue to integrate this expertise into our ongoing programme of work. For example, we will develop and implement state-of-the-art methodology in MA and NMA of time-to-event outcomes based on individual participant data (IPD), informing overall and stratified treatment decisions, while allowing for complexities in the design of the component trials, heterogeneity between trials, and inconsistency between direct and indirect evidence.
Our overall philosophy is to use the simplest methods that can be shown to be valid (often by methodological comparison with more complex methods), and wherever possible to work prospectively and collaboratively to reduce bias, increase the timeliness of our reviews, and achieve greater impact.
Our research covers four priority areas:
1. Beyond standard systematic reviews – developing review methods that move beyond standard approaches and using them to perform high-quality and challenging reviews
2. Determining methods to assess which participants benefit most from treatments in pairwise and network meta-analysis
3. Choosing and building appropriate models for in pairwise and network meta-analysis
4. Guidance and tools to increase impact of our meta-analysis methods
Organisations
- UNIVERSITY COLLEGE LONDON (Lead Research Organisation)
- University of Milan (Collaboration)
- University of Gothenburg (Collaboration)
- Carolina Urologic Research Center (Collaboration)
- Aix-Marseille University (Collaboration)
- University of Granada (Collaboration)
- Kindai University Hospital (Collaboration)
- Leiden University Medical Center (Collaboration)
- Prostate Cancer Foundation (Collaboration)
- Hospital Reina SofÃa de Córdoba (Collaboration)
- University of Maryland (Collaboration)
- Epsom and St Helier University Hospitals NHS Trust (Collaboration)
- QUEEN'S UNIVERSITY BELFAST (Collaboration)
- University Children's Hospital Zurich (Collaboration)
- The Methodist Hospital, Houston (Collaboration)
- Massachusetts General Hospital (Collaboration)
- Public Assistance - Hospitals of Paris (Collaboration)
- UNIVERSITY OF BIRMINGHAM (Collaboration)
- University of Texas (Collaboration)
- Yokohama City University Medical Centre (Collaboration)
- Saint Louis University (Collaboration)
- University of Miami (Collaboration)
- AstraZeneca (Collaboration)
- University of Michigan (Collaboration)
- University of Port Harcourt Teaching Hospital (Collaboration)
- Sapienza University of Rome (Collaboration)
- Circolo Hospital and Macchi Foundation (Collaboration)
- Oregon Health and Science University (Collaboration)
- Mohamed V University (Collaboration)
- Akershus University Hospital (Collaboration)
- University of Lille (Collaboration)
- University of Pennsylvania (Collaboration)
- Royal Victoria Hospital, Belfast (Collaboration)
- University of Wurzburg (Collaboration)
- Tata Memorial Hospital (Collaboration)
- Institute of Cancer Research UK (Collaboration)
- Health Data Research UK (Collaboration)
- University Hospital of Valme (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- Santa Chiara Hospital (Collaboration)
- Toho University Medical Center Sakura Hospital (Collaboration)
- University of Sydney (Collaboration)
- Oslo University Hospital (Collaboration)
- Grochowski Hospital (Collaboration)
- Umea University (Collaboration)
- Stanford University (Collaboration)
- Camden and Islington NHS Foundation Trust (Collaboration)
- Tel Aviv University (Collaboration)
- National Institute for Health and Care Research (Collaboration)
- University of Leipzig (Collaboration)
- University of Adelaide (Collaboration)
- UNIVERSITY OF LIVERPOOL (Collaboration)
- University of Melbourne (Collaboration)
- Yale University (Collaboration)
- Beneficência Portuguesa de São Paulo (Collaboration)
- Institute of Health Carlos III (Collaboration)
- Sun Yat-sen University (Collaboration)
- University College London (Collaboration)
- UNIVERSITY OF MALAYA (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
- Fiona Stanley Hospital (Collaboration)
- Medical University of Vienna (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- National Cancer Centre Singapore (Collaboration)
- Skåne University Hospital (Collaboration)
- University of Paris (Collaboration)
- Sanofi (Collaboration)
- Hospital Ramón y Cajal (Collaboration)
- University Hospital Erlangen (Collaboration)
- Keele University (Collaboration)
- University of Hong Kong (Collaboration)
- Lille University Hospital (Collaboration)
- Netherlands Cancer Institute (NKI) (Collaboration)
- University of Ioannina (Collaboration)
- University Hospital La Princesa (Collaboration)
- UNIVERSITY OF YORK (Collaboration)
- Karolinska Institute (Collaboration)
- University Hospital Schleswig-Holstein (Collaboration)
- Barts Health NHS Trust (Collaboration)
- Connolly Hospital Blanchardstown (Collaboration)
- Babes-Bolyai University (Collaboration)
- Antwerp University Hospital (Collaboration)
- Sahlgrenska University Hospital (Collaboration)
- NRG Oncology (Collaboration)
- UNIVERSITY OF LEEDS (Collaboration)
- Fudan University (Collaboration)
- University of Côte d'Azur (Collaboration)
- UNIVERSITY OF SOUTHAMPTON (Collaboration)
- ROYAL MARSDEN NHS FOUNDATION TRUST (Collaboration)
- University of Wisconsin-Madison (Collaboration)
- National Institute of Health and Medical Research (INSERM) (Collaboration)
- Li Ka Shing Foundation (Collaboration)
- University of Paris - Descartes (Collaboration)
- SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- Berry Consultants LLC (Collaboration)
- University of Utah (Collaboration)
- University of Chicago Medical Center (Collaboration)
- Gustave-Roussy Institute (Collaboration)
- Free University of Amsterdam (Collaboration)
- St Luke's Hospital, Dublin (Collaboration)
- Dana-Farber Cancer Institute (Collaboration)
- Saitama Medical University (Collaboration)
- University of Glasgow (Collaboration)
- Belfast City Hospital (Collaboration)
- Saarland University (Collaboration)
- University of California, San Francisco (Collaboration)
- Hospital of Clinics of Porto Alegre (Collaboration)
- UNIVERSITY OF MANCHESTER (Collaboration)
- University of Paris-Saclay (Collaboration)
- Hospital de Sant Pau (Collaboration)
- Hospital Universitario Puerta de Hierro (Collaboration)
- Hong Kong Sanatorium and Hospital (Collaboration)
- Albert Ludwig University of Freiburg (Collaboration)
- University of Lugano (Collaboration)
- University of Southern California (Collaboration)
- Paoli-Calmettes Institute (Collaboration)
- Federal University of Rio Grande do Sul (Collaboration)
- World Health Organization (WHO) (Collaboration)
- Mount Vernon Hospital (Collaboration)
- Necker-Enfants Malades Hospital (Collaboration)
- University of Western Australia (Collaboration)
- Vall d'Hebron Institute of Oncology (Collaboration)
- University of North Carolina at Chapel Hill (Collaboration)
- American University of Beirut Medical Center (Collaboration)
- Deakin University (Collaboration)
- Ghent University Hospital (Collaboration)
- Maastricht University (UM) (Collaboration)
- San Raffaele Hospital (Collaboration)
- Innlandet Hospital Trust (Collaboration)
- Hospital 12 de Octubre (Collaboration)
- Queen's Medical Center (Collaboration)
- Walsall College (Collaboration)
- The Hospital Israelita Albert Einstein (Collaboration)
- Cleveland Clinic (Collaboration)
- Tampere University Hospital (Collaboration)
- Technical University of Munich (Collaboration)
- University of Minnesota (Collaboration)
- Baylor College of Medicine (Collaboration)
- King Saud University (Collaboration)
- Peking University (Collaboration)
- Johns Hopkins University (Collaboration)
- University of Oxford (Collaboration)
- University of Cape Town (Collaboration)
- Pumping Marvellous Foundation (Collaboration)
- Vanderbilt University (Collaboration)
- Hospitals Essen-Mitte (Collaboration)
- University Hospitals Seidman Cancer Center (Collaboration)
- University of Greifswald (Collaboration)
- Curie Institute Paris (Institut Curie) (Collaboration)
- Leiden University (Collaboration)
- University of Copenhagen (Collaboration)
- University of Franche-Comté (Collaboration)
- University of Toronto (Collaboration)
- Royal Marsden Hospital (Collaboration)
- Flinders University (Collaboration)
- Albert Schweitzer Hospital (Collaboration)
- University of British Columbia (Collaboration)
- Tulane Medical Center (Collaboration)
- University of Twente (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- Duke University (Collaboration)
- UNIVERSITY OF EXETER (Collaboration)
- Saint Michael's Hospital (Collaboration)
- Radboud University Nijmegen Medical Center (Collaboration)
- University of Zurich (Collaboration)
- University of Bern (Collaboration)
- Centre Eugène Marquis (Collaboration)
- SOMERSET NHS FOUNDATION TRUST (Collaboration)
- Northwestern University (Collaboration)
- Karolinska University Hospital (Collaboration)
- Australian Institute of Family Studies (Collaboration)
- Ann Arbor VA Medical Center (Collaboration)
- Swiss Group for Cancer Clinical Research (SAKK) (Collaboration)
- QUEEN MARY UNIVERSITY OF LONDON (Collaboration)
- Fundación Marques de Valdecilla (Collaboration)
- McMaster University (Collaboration)
- Radboud University Nijmegen (Collaboration)
- UNIVERSITY OF LEICESTER (Collaboration)
- CAMBRIDGESHIRE AND PETERBOROUGH NHS FOUNDATION TRUST (Collaboration)
- NewYork-Presbyterian Hospital (Collaboration)
- University of Colorado (Collaboration)
- Erasmus MC (Collaboration)
- Regeneron Pharmaceuticals, Inc. (Collaboration)
- N.N. Alexandrov National Cancer Centre of Belarus (Collaboration)
- University Medical Center Hamburg-Eppendorf (Collaboration)
- California Pacific Medical Center (Collaboration)
- University of Montreal (Collaboration)
- Peter MacCallum Cancer Centre (Collaboration)
- Copenhagen University Hospital (Collaboration)
- George Institute for Global Health (Collaboration)
- UNIVERSITY OF BRISTOL (Collaboration)
- European Organisation for Research and Treatment of Cancer (EORTC) (Collaboration)
- University of Connecticut (Collaboration)
- University of California (Collaboration)
- Christus Health (Collaboration)
- University of Kyoto (Collaboration)
- Turku University Hospital (Collaboration)
- UNIVERSITY OF EAST ANGLIA (Collaboration)
- University of South Florida (Collaboration)
- Essen University Hospital (Collaboration)
- Hebrew University of Jerusalem (Collaboration)
- THE CHRISTIE NHS FOUNDATION TRUST (Collaboration)
- Harvard University (Collaboration)
- University Medical Center Utrecht (UMC) (Collaboration)
- ANKARA UNIVERSITY (Collaboration)
- University of Kiel (Collaboration)
- MONASH UNIVERSITY (Collaboration)
- University of California, Davis (Collaboration)
- Catholic University of Louvain (Collaboration)
- Instituto de Investigación Biomédica de Málaga (Collaboration)
- Cornell University (Collaboration)
- Memorial Sloan Kettering Cancer Center (Collaboration)
- Icahn School of Medicine at Mount Sinai (Collaboration)
- Hillingdon Hospital, Uxbridge (Collaboration)
- UNIVERSITY HOSPITALS BRISTOL AND WESTON NHS FOUNDATION TRUST (Collaboration)
- GUY'S AND ST THOMAS' NHS FOUNDATION TRUST (Collaboration)
- Salford Royal Hospital (Collaboration)
- Ministry of Health (Collaboration)
- University of Padova (Collaboration)
- University of Hasselt (Collaboration)
- North Carolina Institute of Medicine (Collaboration)
- Brussels Saint-Luc University Hospital (UCL) (Collaboration)
- University of Bologna (Collaboration)
- University of New South Wales (Collaboration)
- Alexander Fleming Institute (Collaboration)
- Cantonal Hospital St. Gallen (Collaboration)
- Queensland Government (Collaboration)
- University of Groningen (Collaboration)
- Acibadem University (Collaboration)
- University of Washington (Collaboration)
- OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- University of Queensland (Collaboration)
- Fred Hutchinson Cancer Research Center (FHCRC) (Collaboration)
- Genentech, Inc (Collaboration)
Publications
Adams R
(2021)
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis.
in Cancer treatment reviews
Advanced Bladder Cancer (ABC) Meta-Analysis Collaborators Group
(2022)
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.
in European urology
Al Wattar B
(2024)
Effectiveness and safety of menopause treatments: pitfalls of available evidence and future research need
in Climacteric
Al Wattar BH
(2024)
Effectiveness of treatment options for tubal ectopic pregnancy: A systematic review and network meta-analysis.
in BJOG : an international journal of obstetrics and gynaecology
Buckman JEJ
(2021)
The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis.
in Psychological medicine
Buckman JEJ
(2023)
Predicting prognosis for adults with depression using individual symptom data: a comparison of modelling approaches.
in Psychological medicine
Buckman JEJ
(2021)
Is social support pre-treatment associated with prognosis for adults with depression in primary care?
in Acta psychiatrica Scandinavica
Cabrit N
(2025)
Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy
in European Journal of Cancer
Chiocchia V
(2023)
The complexity underlying treatment rankings: how to use them and what to look at.
in BMJ evidence-based medicine
| Guideline Title | Covid Guidelines India |
| Description | Anti-IL6 COVID-19 SR (PMID:34228774) CMGIG guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline |
| Description | Anti-IL6 COVID-19 SR (PMID:34228774) ERS guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | IDSA Guidelines on the Treatment and Management of Patients with COVID-19 |
| Description | Anti-IL6 COVID-19 SR (PMID:34228774) IDSA guideline 2022 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Interim Clinical Commissioning Policy: IL-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 (adults) |
| Description | Anti-IL6 COVID-19 SR (PMID:34228774) NHS guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Therapeutics and COVID-19: Living Guideline. 6 July 2021 |
| Description | Anti-IL6 COVID-19 SR (PMID:34228774) WHO guideline 2021 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Therapeutics and COVID-19: Living Guideline. 18 August 2023 |
| Description | Anti-IL6 COVID-19 SR (PMID:34228774) WHO guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms |
| Description | Bladder Adj CT IPD (PMID: 15939530) GGPO guideline 2024 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/ |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic Bladder cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.6.2021 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2021 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.3.2022 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2024 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2024 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.6.2024 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2024 (v6) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical Practice Guideline GU-013 Version 8 (Muscle Invasive Bladder Cancer) (2021) |
| Description | Bladder Adj CT IPD (PMID:16625650) AHS guideline 2023 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical Practice Guideline GU-013 Version 9 (Muscle Invasive Bladder Cancer) (2024) |
| Description | Bladder Adj CT IPD (PMID:16625650) AHS guideline 2024 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic Bladder cancer |
| Description | Bladder Adj CT IPD 2005 (PMID:15939530) EAU guideline 2023 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic Bladder cancer (2024) |
| Description | Bladder Adj CT IPD 2005 (PMID:15939530) EAU guideline 2024 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic Bladder cancer (2024) |
| Description | Bladder Adj CT IPD 2021 (PMID:34802798) EAU guideline 2024 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | 2024 CUA-GUMOC Expert Report: Management of unresectable locally advanced and metastatic urothelial carcinoma |
| Description | Bladder Neo CT IPD (PMID: 15939524) CUA Expert Report 2024 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | CUA guideline: Muscle-invasive bladder cancer (2025) |
| Description | Bladder Neo CT IPD (PMID: 15939524) CUA guideline 2025 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic (2021) |
| Description | Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/ |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic (2022) |
| Description | Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic (2024) |
| Description | Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2024 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Bladder Neo CT IPD (PMID: 15939524) ESMO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.esmo.org/guidelines/genitourinary-cancers/bladder-cancer |
| Guideline Title | Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up (eUpdate 2024) |
| Description | Bladder Neo CT IPD (PMID: 15939524) ESMO guideline 2024 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms |
| Description | Bladder Neo CT IPD (PMID: 15939524) GGPO guideline 2024 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 6.2021 |
| Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2021 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 3.2022 |
| Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2024 |
| Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2024 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 6.2024 |
| Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2024v6 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | SEOM-SOGUG clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2021) |
| Description | Bladder Neo CT IPD (PMID: 15939524) SEOM-SOGUG guideline 2021 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | SEOM-SOGUG clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2021) |
| Description | Bladder Neo CT IPD (PMID: 34802798) SEOM-SOGUG guideline 2021 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical Practice Guideline GU-013 Version 6 (Muscle Invasive Bladder Cancer) (2021) |
| Description | Bladder Neo CT IPD (PMID:15846746) AHS Guideline 2021 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical Practice Guideline GU-013 Version 8 (Muscle Invasive Bladder Cancer) (2023) |
| Description | Bladder Neo CT IPD (PMID:15939524) AHS Guideline 2023 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical Practice Guideline GU-013 Version 9 (Muscle Invasive Bladder Cancer) (2024) |
| Description | Bladder Neo CT IPD (PMID:15939524) AHS Guideline 2025 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.1 2021 |
| Description | Cervix CTRT IPD (PMID: 19001332) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Diagnostik_Therapie_Nachsorge_Zervixkarzi... |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.1 2021 |
| Description | Cervix CTRT IPD (PMID: 19001332) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Diagnostik_Therapie_Nachsorge_Zervixkarzi... |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022 |
| Description | Cervix CTRT IPD (PMID: 19001332) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2022 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2022 (1) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2023 (1) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1 2024 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2024 (1) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.3 2025 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2025 (3) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | SEOM-GEICO clinical guidelines for cervical cancer 2023 |
| Description | Cervix CTRT IPD (PMID:19001332) SEOM-GEICO guideline 2023 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2022 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:20091632) NCCN guideline 2022 (1) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:20091632) NCCN guideline 2023 (1) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2024 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:20091632) NCCN guideline 2024 (1) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.3.2025 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:20091632) NCCN guideline 2025 (3) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022 |
| Description | Cervix CTRT SR (PMID: 16034873) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update |
| Description | Cervix Neo CT IPD (PMID: 15106161) ASCO guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Cancer of the Uterine Cervix |
| Description | Cervix Neo CT SR (PMID:23235641) AHS guideline 2021 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gyne004-cervical.pdf |
| Guideline Title | Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update |
| Description | Cervix Neo CT SR (PMID:23235641) ASCO guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.1 2021 |
| Description | Cervix Neo CT SR (PMID:23235641) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Diagnostik_Therapie_Nachsorge_Zervixkarzi... |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022 |
| Description | Cervix Neo CT SR (PMID:23235641) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Therapeutics and COVID-19: Living Guideline |
| Description | Corticosteroids COVID-19 SR (PMID:32876694) WHO guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie endometrriumkarzinom V2.0 (2022) |
| Description | Endometrial CT SR (PMID: 22895938) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie endometrriumkarzinom V3.01 (2023) |
| Description | Endometrial CT SR (PMID: 22895938) GGPO guideline 2023 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1 2022. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline 2022 (V1) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1 2024. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline 2024 (V1) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2 2025. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline 2025 (V2) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Description | IW on CRUK funding panel |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2024. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2024 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2025. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2025 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update |
| Description | Lung Adj CT IPD (PMID:25730344) ASCO guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update |
| Description | Lung CT 95 IPD (PMID:7580546) ASCO guideline stage I-III NSCLC 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative |
| Description | Lung CT 95 IPD (PMID:7580546) CSCO-ESMO guideline 2018 |
| Geographic Reach | Asia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2023 |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2025. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2025 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
| Description | Lung Neo CT IPD (PMID: 24576776) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V4.01 (2024) |
| Description | Lung Neo CT IPD (PMID: 24576776) GGPO guideline 2023 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2023) |
| Description | Lung Neo CT IPD (PMID: 24576776) GGPO guideline 2023 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer |
| Description | Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer |
| Description | Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2025. Non-Small Cell Lung Cancer |
| Description | Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2025 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
| Description | Lung PORT IPD (PMID: 9690404) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2023) |
| Description | Lung PORT IPD (PMID: 9690404) GGPO guideline 2023 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V4.01 (2024) |
| Description | Lung PORT IPD (PMID: 9690404) GGPO guideline 2024 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2024. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2024 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2025. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2025 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update |
| Description | Lung PORT IPD (PMID: 9690404; 23453644) ASCO guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
| Description | Lung SC IPD (PMID: 18678835) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2024) |
| Description | Lung SC IPD (PMID: 18678835) GGPO guideline 2023 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V4.01 (2024) |
| Description | Lung SC IPD (PMID: 18678835) GGPO guideline 2024 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2025. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2025 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
| Description | Lung SC IPD (PMID: 25730344) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2023) |
| Description | Lung SC IPD (PMID: 25730344) GGPO guideline 2023 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V4.01 (2024) |
| Description | Lung SC IPD (PMID: 25730344) GGPO guideline 2024 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative |
| Description | Lung SC IPD (PMID:18678835) CSCO-ESMO guideline 2018 |
| Geographic Reach | Asia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2023) |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) GGPO guideline 2023 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V4.01 (2024) |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) GGPO guideline 2023 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v1.2022. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v1.2023. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v2.2024. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2024 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v3.2025. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2025 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Description | Network software recommended in Cochrane handbook |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Systematic reviewers are encouraged to use reliable and easy-to-use software for performing network meta-analysis. |
| URL | https://training.cochrane.org/handbook/current/chapter-11#section-11-4 |
| Guideline Title | Leitlinienprogramm onkologie. Diagnostik und therapie des Ösophaguskarzinoms v3.0 2021 |
| Description | Oesophagus RT IPD (PMID:16235286) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.leitlinienprogramm-onkologie.de/leitlinien/oesophaguskarzinom/ |
| Guideline Title | Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. V3.1 (2022) |
| Description | Oesophagus RT IPD (PMID:16235286) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. V4.0 (2023) |
| Description | Oesophagus RT IPD (PMID:16235286) GGPO guideline 2023 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Guidelines Version 1.2022 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Guidelines Version 5.2022 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2022 (v5) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Guidelines Version 4.2023 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2023 (v4) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Guidelines Version 5.2024 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2024 (v5) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Local Prostate Cancer |
| Description | Prostate ARTISTIC AD (PMID: 33002431) AHS guideline 2024 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Linee guida: CARCINOMA DELLA PROSTATA |
| Description | Prostate ARTISTIC AD (PMID: 33002431) AIOM guideline 2024 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) |
| Description | Prostate ARTISTIC AD (PMID: 33002431) APCCC guideline 2024 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer (2024) |
| Description | Prostate ARTISTIC AD (PMID: 33002431) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guideline 2024 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2021) |
| Description | Prostate Abi AD (PMID: 28800492) EAU guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2022) |
| Description | Prostate Abi AD (PMID: 28800492) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2023) |
| Description | Prostate Abi AD (PMID: 28800492) EAU guideline 2023 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer (2024) |
| Description | Prostate Abi AD (PMID: 28800492) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guideline 2024 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Local Prostate Cancer |
| Description | Prostate Artistic AD (PMID: 33002431) AHS guideline 2021 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gu012-local-prostate.p... |
| Guideline Title | Local Prostate Cancer |
| Description | Prostate Artistic AD (PMID: 33002431) AHS guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinically Localized Prostate Cancer: AUA/ASTRO Guideline (2022) |
| Description | Prostate Artistic AD (PMID: 33002431) AUA/ASTRO guideline 2022 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2021) |
| Description | Prostate Artistic AD (PMID: 33002431) EAU guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://uroweb.org/guideline/prostate-cancer/ |
| Guideline Title | EAU Guideline: Prostate Cancer (2022) |
| Description | Prostate Artistic AD (PMID: 33002431) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2023) |
| Description | Prostate Artistic AD (PMID: 33002431) EAU guideline 2023 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Leitlinie Prostatakarzinom v6.2 2021 |
| Description | Prostate Artistic AD (PMID: 33002431) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.2.2022 Prostate Cancer |
| Description | Prostate Artistic AD (PMID: 33002431) NCCN guideline 2021 V2 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Prostate Cancer |
| Description | Prostate Artistic AD (PMID: 33002431) NCCN guideline 2023 V1 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.4.2023 Prostate Cancer |
| Description | Prostate Artistic AD (PMID: 33002431) NCCN guideline 2023 V4 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Pan-Asian adapted ESMO Guidelines (2022) |
| Description | Prostate Artistic AD (PMID: 33002431) PAGA ESMO guideline 2022 |
| Geographic Reach | Asia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2022) |
| Description | Prostate CT SR (PMID: 26718929) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2023) |
| Description | Prostate CT SR (PMID: 26718929) EAU guideline 2023 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Leitlinie Prostatakarzinom v6.2 2021 |
| Description | Prostate CT SR (PMID: 26718929) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.2.2022 Prostate Cancer |
| Description | Prostate CT SR (PMID: 26718929) NCCN guideline 2021 V2 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Prostate Cancer |
| Description | Prostate CT SR (PMID: 26718929) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Pan-Asian adapted ESMO Guidelines (2022) |
| Description | Prostate CT SR (PMID: 26718929) PAGA ESMO guideline 2022 |
| Geographic Reach | Asia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Prostate Cancer |
| Description | Prostate CT SR (PMID: 30826218) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.4.2023 Prostate Cancer |
| Description | Prostate CT SR (PMID: 30826218) NCCN guideline 2023 v4 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) |
| Description | Prostate DADSPORT AD (No PMID) APCCC guideline 2024 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) |
| Description | Prostate DOC IPD (PMID: 37414011) APCCC guideline 2024 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer (2024) |
| Description | Prostate DOC IPD (PMID: 37414011) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guideline 2024 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer (2024) |
| Description | Prostate Doc Bis AD (PMID: 26718929) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guideline 2024 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prostate cancer v1.2025 |
| Description | Prostate Network AD (PMID: 26718929) NCCN guideline 2025 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2021) |
| Description | Prostate Network AD (PMID: 29788164) EAU guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://uroweb.org/guideline/prostate-cancer/ |
| Guideline Title | EAU Guideline: Prostate Cancer (2022) |
| Description | Prostate Network AD (PMID: 29788164) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prostate cancer v1.2025 |
| Description | Prostate Network AD (PMID: 29788164) NCCN guideline 2025 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Linee guida: CARCINOMA DELLA PROSTATA |
| Description | Prostate RT AD (PMID: 30826218) AIOM guideline 2024 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | 2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer |
| Description | Prostate RT AD (PMID: 30826218) CUA guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2021) |
| Description | Prostate RT AD (PMID: 30826218) EAU guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://uroweb.org/guideline/prostate-cancer/ |
| Guideline Title | EAU Guideline: Prostate Cancer (2022) |
| Description | Prostate RT AD (PMID: 30826218) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2023) |
| Description | Prostate RT AD (PMID: 30826218) EAU guideline 2023 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer (2024) |
| Description | Prostate RT AD (PMID: 30826218) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guideline 2024 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Leitlinie Prostatakarzinom v6.2 2021 |
| Description | Prostate RT AD (PMID: 30826218) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ |
| Guideline Title | Leitlinie Prostatakarzinom v7.0 2024 |
| Description | Prostate RT AD (PMID: 30826218) GGPO guideline 2024 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Leitlinie Prostatakarzinom v7.0 2024 |
| Description | Prostate RT AD (PMID: 33002431) GGPO guideline 2024 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v2.2022 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline 2021 (V2) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v3.2023 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline 2023 (V3) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v4.2024 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline 2024 (V4) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | SEOM Clinical Guideline of management of soft-tissue sarcoma (2020) |
| Description | Sarcoma CT IPD (PMID:9400508) SEOM guideline 2020 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2021 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2021 (V2) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2022 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2022 (V2) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.3.2023 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2023 (V3) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.4.2024 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2024 (V4) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Description | NIHR Development and Skills Enhancement Award |
| Amount | £34,926 (GBP) |
| Funding ID | NIHR301653 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 03/2022 |
| Description | STOPCAP 2: Maximising patient benefit through enhanced evaluation of therapies and better characterisation of metastatic hormone-sensitive prostate cancer |
| Amount | £1,733,200 (GBP) |
| Funding ID | MA-TIA23-007 |
| Organisation | Prostate Cancer UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2024 |
| End | 10/2029 |
| Description | TMRP Doctoral Training Programme |
| Amount | £2,518,806 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2021 |
| End | 09/2026 |
| Description | Towards more trustworthy evidence for all - developing a framework for best practice IPD meta-analysis |
| Amount | $21,950 (AUD) |
| Organisation | University College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 03/2025 |
| Description | Towards more trustworthy evidence for all - developing a framework for best practice IPD meta-analysis |
| Amount | $21,950 (AUD) |
| Organisation | University College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 03/2025 |
| Title | ??.xlsx |
| Description | Meta-analysis metadata of the impact of climate change on soil nematodes |
| Type Of Material | Database/Collection of data |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| URL | https://figshare.com/articles/dataset/_xlsx/26380591/1 |
| Title | ??.xlsx |
| Description | Meta-analysis metadata of the impact of climate change on soil nematodes |
| Type Of Material | Database/Collection of data |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| URL | https://figshare.com/articles/dataset/_xlsx/26380591 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | Circolo Hospital and Macchi Foundation |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | European Organisation for Research and Treatment of Cancer (EORTC) |
| Country | Belgium |
| Sector | Charity/Non Profit |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | N.N. Alexandrov National Cancer Centre of Belarus |
| Country | Belarus |
| Sector | Private |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | NewYork-Presbyterian Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | Saarland University |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | Saint Louis University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | Sapienza University of Rome |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | The Christie NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | University Hospital Erlangen |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | University of Connecticut |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | University of Kiel |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | University of Southern California |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis |
| Organisation | Antwerp University Hospital |
| Country | Belgium |
| Sector | Hospitals |
| PI Contribution | Conception; First drafts of protocol; Protocol finalisation and submission |
| Collaborator Contribution | Commenting on protocol |
| Impact | Protocol: PROSPERO CRD42023453156 |
| Start Year | 2021 |
| Description | Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis |
| Organisation | Cantonal Hospital St. Gallen |
| Country | Switzerland |
| Sector | Hospitals |
| PI Contribution | Conception; First drafts of protocol; Protocol finalisation and submission |
| Collaborator Contribution | Commenting on protocol |
| Impact | Protocol: PROSPERO CRD42023453156 |
| Start Year | 2021 |
| Description | Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Conception; First drafts of protocol; Protocol finalisation and submission |
| Collaborator Contribution | Commenting on protocol |
| Impact | Protocol: PROSPERO CRD42023453156 |
| Start Year | 2021 |
| Description | Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis |
| Organisation | Leiden University Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Conception; First drafts of protocol; Protocol finalisation and submission |
| Collaborator Contribution | Commenting on protocol |
| Impact | Protocol: PROSPERO CRD42023453156 |
| Start Year | 2021 |
| Description | Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis |
| Organisation | National Cancer Centre Singapore |
| Country | Singapore |
| Sector | Hospitals |
| PI Contribution | Conception; First drafts of protocol; Protocol finalisation and submission |
| Collaborator Contribution | Commenting on protocol |
| Impact | Protocol: PROSPERO CRD42023453156 |
| Start Year | 2021 |
| Description | Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis |
| Organisation | Oslo University Hospital |
| Country | Norway |
| Sector | Hospitals |
| PI Contribution | Conception; First drafts of protocol; Protocol finalisation and submission |
| Collaborator Contribution | Commenting on protocol |
| Impact | Protocol: PROSPERO CRD42023453156 |
| Start Year | 2021 |
| Description | Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis |
| Organisation | Saitama Medical University |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | Conception; First drafts of protocol; Protocol finalisation and submission |
| Collaborator Contribution | Commenting on protocol |
| Impact | Protocol: PROSPERO CRD42023453156 |
| Start Year | 2021 |
| Description | Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis |
| Organisation | Swiss Group for Cancer Clinical Research (SAKK) |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Conception; First drafts of protocol; Protocol finalisation and submission |
| Collaborator Contribution | Commenting on protocol |
| Impact | Protocol: PROSPERO CRD42023453156 |
| Start Year | 2021 |
| Description | Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis |
| Organisation | Tata Memorial Hospital |
| Country | India |
| Sector | Hospitals |
| PI Contribution | Conception; First drafts of protocol; Protocol finalisation and submission |
| Collaborator Contribution | Commenting on protocol |
| Impact | Protocol: PROSPERO CRD42023453156 |
| Start Year | 2021 |
| Description | Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Conception; First drafts of protocol; Protocol finalisation and submission |
| Collaborator Contribution | Commenting on protocol |
| Impact | Protocol: PROSPERO CRD42023453156 |
| Start Year | 2021 |
| Description | Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Conception; First drafts of protocol; Protocol finalisation and submission |
| Collaborator Contribution | Commenting on protocol |
| Impact | Protocol: PROSPERO CRD42023453156 |
| Start Year | 2021 |
| Description | Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis |
| Organisation | University of Sydney |
| Department | NHMRC Clinical Trials Centre |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Conception; First drafts of protocol; Protocol finalisation and submission |
| Collaborator Contribution | Commenting on protocol |
| Impact | Protocol: PROSPERO CRD42023453156 |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Albert Schweitzer Hospital |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Ann Arbor VA Medical Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Beneficência Portuguesa de São Paulo |
| Country | Brazil |
| Sector | Charity/Non Profit |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Berry Consultants LLC |
| Country | United States |
| Sector | Private |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Genentech, Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Ghent University Hospital |
| Country | Belgium |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Health Data Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Hebrew University of Jerusalem |
| Department | Hebrew University Hadassah Medical School |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Hospital Ramón y Cajal |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Hospital Reina SofÃa de Córdoba |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Hospital Universitario Puerta de Hierro |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Hospital de Sant Pau |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Karolinska University Hospital |
| Country | Sweden |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Ministry of Health |
| Country | Malaysia |
| Sector | Public |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Department | INSERM U1153 (Center for Epidemiology and Biostatistics) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Necker-Enfants Malades Hospital |
| Country | France |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Public Assistance - Hospitals of Paris |
| Country | France |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Queen's Medical Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Regeneron Pharmaceuticals, Inc. |
| Country | United States |
| Sector | Private |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Sanofi |
| Department | Genzyme Corporation |
| Country | United States |
| Sector | Private |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Turku University Hospital |
| Country | Finland |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University Hospital La Princesa |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University Hospital of Valme |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University Hospitals Bristol and Weston NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University Medical Center Utrecht (UMC) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of British Columbia |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Chicago Medical Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Groningen |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Malaya |
| Country | Malaysia |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Melbourne |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Oxford |
| Department | Nuffield Department of Population Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Paris |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Toronto |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | World Health Organization (WHO) |
| Country | Switzerland |
| Sector | Public |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review |
| Organisation | Barts Health NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Design of the review; advised on methodology and contributed to and approved the final manuscript |
| Collaborator Contribution | Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript |
| Impact | 1 protocol, and 1 paper (PMID: 34404753) |
| Start Year | 2018 |
| Description | Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Design of the review; advised on methodology and contributed to and approved the final manuscript |
| Collaborator Contribution | Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript |
| Impact | 1 protocol, and 1 paper (PMID: 34404753) |
| Start Year | 2018 |
| Description | Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review |
| Organisation | Queen Mary University of London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Design of the review; advised on methodology and contributed to and approved the final manuscript |
| Collaborator Contribution | Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript |
| Impact | 1 protocol, and 1 paper (PMID: 34404753) |
| Start Year | 2018 |
| Description | Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review |
| Organisation | University College London |
| Department | Lungs for Living Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Design of the review; advised on methodology and contributed to and approved the final manuscript |
| Collaborator Contribution | Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript |
| Impact | 1 protocol, and 1 paper (PMID: 34404753) |
| Start Year | 2018 |
| Description | Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review |
| Organisation | University of Leicester |
| Department | Respiratory Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Design of the review; advised on methodology and contributed to and approved the final manuscript |
| Collaborator Contribution | Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript |
| Impact | 1 protocol, and 1 paper (PMID: 34404753) |
| Start Year | 2018 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | Babes-Bolyai University |
| Country | Romania |
| Sector | Academic/University |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | Federal University of Rio Grande do Sul |
| Country | Brazil |
| Sector | Academic/University |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | Free University of Amsterdam |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | Hospital of Clinics of Porto Alegre |
| Country | Brazil |
| Sector | Hospitals |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Department | NIHR Oxford Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | Technical University of Munich |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | University of Cape Town |
| Country | South Africa |
| Sector | Academic/University |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | University of Colorado |
| Department | University of Colorado Anschutz Medical Campus |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | University of Kyoto |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | University of Melbourne |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis |
| Organisation | University of Toronto |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Helped to develop a detailed data collection and analysis plan and critically revised the results from the statistical analysis All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Collaborator Contribution | Partners conceived and designed the study; developed a detailed data collection and analysis plan; selected the articles and extracted the data; curated the data; analysed the data; critically revised the results from the statistical analysis and wrote the first draft of the manuscript All authors contributed to the finalisation of the methods, analysis findings, and to the writing of the final version of the manuscript and agreed with the results and conclusions of this article |
| Impact | One protocol (PROSPERO (CRD42020180049) One publication (doi: 10.48620/403) |
| Start Year | 2021 |
| Description | Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation |
| Organisation | Pumping Marvellous Foundation |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report |
| Impact | 1 protocol, and 1 paper (PMID: 35076012) |
| Start Year | 2018 |
| Description | Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation |
| Organisation | Somerset NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report |
| Impact | 1 protocol, and 1 paper (PMID: 35076012) |
| Start Year | 2018 |
| Description | Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation |
| Organisation | University of Leeds |
| Department | Leeds School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report |
| Impact | 1 protocol, and 1 paper (PMID: 35076012) |
| Start Year | 2018 |
| Description | Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation |
| Organisation | University of Maryland |
| Department | School of Medicine Maryland |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report |
| Impact | 1 protocol, and 1 paper (PMID: 35076012) |
| Start Year | 2018 |
| Description | Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation |
| Organisation | University of York |
| Department | Centre for Reviews and Dissemination (CRD) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report |
| Impact | 1 protocol, and 1 paper (PMID: 35076012) |
| Start Year | 2018 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Akershus University Hospital |
| Country | Norway |
| Sector | Hospitals |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Albert Schweitzer Hospital |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Cornell University |
| Department | Weill Cornell Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Fudan University |
| Country | China |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | George Institute for Global Health |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | McMaster University |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Peking University |
| Country | China |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Radboud University Nijmegen Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Umea University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of British Columbia |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Copenhagen |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Côte d'Azur |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Lille |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Twente |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Western Australia |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Wurzburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Yale University |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Dealing with Missing Data in an IPD Meta-analysis (Chapter 18). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | Maastricht University (UM) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Co-authored the chapter |
| Collaborator Contribution | Co-authored the chapter. One partner led writing the chapter and one was co-editor of book |
| Impact | 1 book chapter (Chapter 18) |
| Start Year | 2015 |
| Description | Dealing with Missing Data in an IPD Meta-analysis (Chapter 18). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | University Medical Center Utrecht (UMC) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Co-authored the chapter |
| Collaborator Contribution | Co-authored the chapter. One partner led writing the chapter and one was co-editor of book |
| Impact | 1 book chapter (Chapter 18) |
| Start Year | 2015 |
| Description | Development of a checklist of standard items for processing individual participant data from randomised trials for meta-analyses: protocol for a modified e-Delphi study |
| Organisation | Deakin University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Members of the research team contributed to the design of the protocol, commented on drafts and advised on the scoping review |
| Collaborator Contribution | Conceptualised design of study, gained funding, developed and drafted protocol. Carried out scoping review |
| Impact | 1 protocol, and 1 paper (PMID: 36219622) |
| Start Year | 2021 |
| Description | Development of a checklist of standard items for processing individual participant data from randomised trials for meta-analyses: protocol for a modified e-Delphi study |
| Organisation | Monash University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Members of the research team contributed to the design of the protocol, commented on drafts and advised on the scoping review |
| Collaborator Contribution | Conceptualised design of study, gained funding, developed and drafted protocol. Carried out scoping review |
| Impact | 1 protocol, and 1 paper (PMID: 36219622) |
| Start Year | 2021 |
| Description | Development of a checklist of standard items for processing individual participant data from randomised trials for meta-analyses: protocol for a modified e-Delphi study |
| Organisation | Queen's University Belfast |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Members of the research team contributed to the design of the protocol, commented on drafts and advised on the scoping review |
| Collaborator Contribution | Conceptualised design of study, gained funding, developed and drafted protocol. Carried out scoping review |
| Impact | 1 protocol, and 1 paper (PMID: 36219622) |
| Start Year | 2021 |
| Description | Development of a checklist of standard items for processing individual participant data from randomised trials for meta-analyses: protocol for a modified e-Delphi study |
| Organisation | University of Sydney |
| Department | NHMRC Clinical Trials Centre |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Members of the research team contributed to the design of the protocol, commented on drafts and advised on the scoping review |
| Collaborator Contribution | Conceptualised design of study, gained funding, developed and drafted protocol. Carried out scoping review |
| Impact | 1 protocol, and 1 paper (PMID: 36219622) |
| Start Year | 2021 |
| Description | Efficacy and moderators of efficacy of trauma-focused cognitive behavioural therapies in children and adolescents: protocol for an individual participant data meta-analysis from randomised trials |
| Organisation | Cambridgeshire and Peterborough NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Contributed to study methods; critically reviewed and approved the final manuscript |
| Collaborator Contribution | Designed the project; critically reviewed and approved the final manuscript. |
| Impact | Protocol - PROSPERO CRD42019151954 Publication of Protocol - doi: 10.1136/bmjopen-2020-047212 |
| Start Year | 2020 |
| Description | Efficacy and moderators of efficacy of trauma-focused cognitive behavioural therapies in children and adolescents: protocol for an individual participant data meta-analysis from randomised trials |
| Organisation | University Children's Hospital Zurich |
| Country | Switzerland |
| Sector | Hospitals |
| PI Contribution | Contributed to study methods; critically reviewed and approved the final manuscript |
| Collaborator Contribution | Designed the project; critically reviewed and approved the final manuscript. |
| Impact | Protocol - PROSPERO CRD42019151954 Publication of Protocol - doi: 10.1136/bmjopen-2020-047212 |
| Start Year | 2020 |
| Description | Efficacy and moderators of efficacy of trauma-focused cognitive behavioural therapies in children and adolescents: protocol for an individual participant data meta-analysis from randomised trials |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed to study methods; critically reviewed and approved the final manuscript |
| Collaborator Contribution | Designed the project; critically reviewed and approved the final manuscript. |
| Impact | Protocol - PROSPERO CRD42019151954 Publication of Protocol - doi: 10.1136/bmjopen-2020-047212 |
| Start Year | 2020 |
| Description | Efficacy and moderators of efficacy of trauma-focused cognitive behavioural therapies in children and adolescents: protocol for an individual participant data meta-analysis from randomised trials |
| Organisation | University of East Anglia |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed to study methods; critically reviewed and approved the final manuscript |
| Collaborator Contribution | Designed the project; critically reviewed and approved the final manuscript. |
| Impact | Protocol - PROSPERO CRD42019151954 Publication of Protocol - doi: 10.1136/bmjopen-2020-047212 |
| Start Year | 2020 |
| Description | Efficacy and moderators of efficacy of trauma-focused cognitive behavioural therapies in children and adolescents: protocol for an individual participant data meta-analysis from randomised trials |
| Organisation | University of Zurich |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Contributed to study methods; critically reviewed and approved the final manuscript |
| Collaborator Contribution | Designed the project; critically reviewed and approved the final manuscript. |
| Impact | Protocol - PROSPERO CRD42019151954 Publication of Protocol - doi: 10.1136/bmjopen-2020-047212 |
| Start Year | 2020 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | Australian Institute of Family Studies |
| Country | Australia |
| Sector | Public |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | Baylor College of Medicine |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | California Pacific Medical Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | Catholic University of Louvain |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | Fiona Stanley Hospital |
| Country | Australia |
| Sector | Hospitals |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | Flinders University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | Johns Hopkins University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | Monash University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | Oregon Health and Science University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | Sahlgrenska University Hospital |
| Country | Sweden |
| Sector | Hospitals |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | Skåne University Hospital |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | University of Adelaide |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | University of California, San Francisco |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | University of Gothenburg |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | University of Greifswald |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | University of New South Wales |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | University of North Carolina at Chapel Hill |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | University of Sydney |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | University of Washington |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | Factors associated with circulating sex hormones in men : individual participant data meta-analyses |
| Organisation | University of Western Australia |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Analysis and interpretation of the data; Statistical expertise; Final approval of the article |
| Collaborator Contribution | Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data. |
| Impact | Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342 |
| Start Year | 2021 |
| Description | IW advisor to Orestis Efthimiou grant |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Advised on development and submission of successful research grant proposal to Swiss National Science Foundation (SNSF). Collaborated on two papers. |
| Collaborator Contribution | Developed and submitted successful research grant proposal to Swiss National Science Foundation (SNSF). Collaborated on two papers. |
| Impact | Two papers published so far. |
| Start Year | 2017 |
| Description | IW collaborator on SNSF grant, PI Georgia Salanti |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Advised on development and submission of successful grant application to SNF. Collaborating on papers. |
| Collaborator Contribution | Developed and submitted successful grant application to SNF. Collaborating on papers. |
| Impact | Multi-disciplinary - epidemiology, systematic review, biostatistics. One publication on treatment hierarchy question. Future impact on conduct of network meta-analysis. |
| Start Year | 2017 |
| Description | IW in ROBIS-NMA group |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed expertise in network meta-analysis |
| Collaborator Contribution | Contributed expertise in systematic review and network meta-analysis |
| Impact | Multidisciplinary work - systematic review and biostatistics. Current outputs - two publications on methods for developing the tool. Future outputs - tool for evaluating risk of bias in a network meta-analysis, expected impact on use of network meta-analysis in health policy making |
| Start Year | 2020 |
| Description | IW in ROBIS-NMA group |
| Organisation | University of Toronto |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Contributed expertise in network meta-analysis |
| Collaborator Contribution | Contributed expertise in systematic review and network meta-analysis |
| Impact | Multidisciplinary work - systematic review and biostatistics. Current outputs - two publications on methods for developing the tool. Future outputs - tool for evaluating risk of bias in a network meta-analysis, expected impact on use of network meta-analysis in health policy making |
| Start Year | 2020 |
| Description | Incorporating dose effects in network meta-analysis |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings |
| Collaborator Contribution | Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback |
| Impact | 1 paper (PMID: 35042687) |
| Start Year | 2016 |
| Description | Incorporating dose effects in network meta-analysis |
| Organisation | Saint Michael's Hospital |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings |
| Collaborator Contribution | Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback |
| Impact | 1 paper (PMID: 35042687) |
| Start Year | 2016 |
| Description | Incorporating dose effects in network meta-analysis |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings |
| Collaborator Contribution | Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback |
| Impact | 1 paper (PMID: 35042687) |
| Start Year | 2016 |
| Description | Incorporating dose effects in network meta-analysis |
| Organisation | University of Ioannina |
| Country | Greece |
| Sector | Academic/University |
| PI Contribution | Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings |
| Collaborator Contribution | Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback |
| Impact | 1 paper (PMID: 35042687) |
| Start Year | 2016 |
| Description | Incorporating dose effects in network meta-analysis |
| Organisation | University of Toronto |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings |
| Collaborator Contribution | Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback |
| Impact | 1 paper (PMID: 35042687) |
| Start Year | 2016 |
| Description | Individual participant data meta-analysis: A handbook for healthcare research (whole book) |
| Organisation | Keele University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Co-editor. Conceived the book concept and planned the outline. Co-authored multiple chapters |
| Collaborator Contribution | Co-editors. Conceived the book concept and planned the outline. Co-authored multiple chapters |
| Impact | 1 book [ISBN: 978-1-119-33372-2] |
| Start Year | 2015 |
| Description | Individual participant data meta-analysis: A handbook for healthcare research (whole book) |
| Organisation | University of York |
| Department | Centre for Reviews and Dissemination (CRD) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Co-editor. Conceived the book concept and planned the outline. Co-authored multiple chapters |
| Collaborator Contribution | Co-editors. Conceived the book concept and planned the outline. Co-authored multiple chapters |
| Impact | 1 book [ISBN: 978-1-119-33372-2] |
| Start Year | 2015 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | Hospital Ramón y Cajal |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | Institute of Health Carlos III |
| Country | Spain |
| Sector | Public |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | Monash University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | Queen Mary University of London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | University of Granada |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Long term pregnancy outcomes of women with cancer following fertility preservation: A systematic review and meta-analysis |
| Organisation | Epsom and St Helier University Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Members of the research team were commented on the protocol, provided feedback and advice during the project, and commented on the final report |
| Collaborator Contribution | Development of the protocol. Performed all trial searches, completed data extraction, analysis and writing the report |
| Impact | 1 protocol (CRD42021269016) and 1 paper (PMID: 36535069) |
| Start Year | 2021 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | Centre Eugène Marquis |
| Country | France |
| Sector | Public |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | Connolly Hospital Blanchardstown |
| Country | Ireland |
| Sector | Hospitals |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | Curie Institute Paris (Institut Curie) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | Erasmus MC |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | Gustave-Roussy Institute |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | Hospitals Essen-Mitte |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | Leiden University |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | Lille University Hospital |
| Country | France |
| Sector | Hospitals |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | NRG Oncology |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | National Institute for Health and Care Research |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | Netherlands Cancer Institute (NKI) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | North Carolina Institute of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | Queensland Government |
| Department | Princess Alexandra Hospital (Australia) |
| Country | Australia |
| Sector | Hospitals |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | St Luke's Hospital, Dublin |
| Country | Ireland |
| Sector | Hospitals |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | Sun Yat-Sen University |
| Country | China |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | University of Hong Kong |
| Country | Hong Kong |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | University of Leipzig |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | University of Michigan |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | University of Padova |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | University of Paris-Saclay |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | University of Queensland |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | University of Sydney |
| Department | NHMRC Clinical Trials Centre |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma |
| Organisation | University of Texas |
| Department | M. D. Anderson Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Conception and design, manuscript writing and final approval of manuscript |
| Collaborator Contribution | Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript |
| Impact | Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279 |
| Start Year | 2018 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Acibadem University |
| Country | Turkey |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Aix-Marseille University |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Alexander Fleming Institute |
| Country | Argentina |
| Sector | Charity/Non Profit |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | American University of Beirut Medical Center |
| Country | Lebanon |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Ankara University |
| Country | Turkey |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Belfast City Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Brussels Saint-Luc University Hospital (UCL) |
| Country | Belgium |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Carolina Urologic Research Center |
| Country | United States |
| Sector | Public |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Cleveland Clinic |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Copenhagen University Hospital |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Cornell University |
| Department | Weill Cornell Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Dana-Farber Cancer Institute |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Duke University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Essen University Hospital |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Fudan University |
| Country | China |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Fundación Marques de Valdecilla |
| Country | Spain |
| Sector | Charity/Non Profit |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Ghent University Hospital |
| Country | Belgium |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Grochowski Hospital |
| Country | Poland |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Gustave-Roussy Institute |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Hong Kong Sanatorium and Hospital |
| Country | Hong Kong |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Hospital 12 de Octubre |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Icahn School of Medicine at Mount Sinai |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Innlandet Hospital Trust |
| Country | Norway |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Instituto de Investigación Biomédica de Málaga |
| Country | Spain |
| Sector | Public |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Kindai University Hospital |
| Country | Japan |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | King Saud University |
| Country | Saudi Arabia |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Medical University of Vienna |
| Country | Austria |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Memorial Sloan Kettering Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Mohamed V University |
| Country | Morocco |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Monash University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Mount Vernon Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | National Cancer Centre Singapore |
| Country | Singapore |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Northwestern University |
| Department | Feinberg School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Oregon Health and Science University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Paoli-Calmettes Institute |
| Country | France |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Peter MacCallum Cancer Centre |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Prostate Cancer Foundation |
| Country | Global |
| Sector | Charity/Non Profit |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Radboud University Nijmegen |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Royal Marsden Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Salford Royal Hospital |
| Department | Christie at Salford Royal Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | San Raffaele Hospital |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Santa Chiara Hospital |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Sheffield Teaching Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Skåne University Hospital |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Stanford University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Tampere University Hospital |
| Country | Finland |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Tata Memorial Hospital |
| Country | India |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Tel Aviv University |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | The Methodist Hospital, Houston |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | The Hospital Israelita Albert Einstein |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Toho University Medical Center Sakura Hospital |
| Country | Japan |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Tulane Medical Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University Hospital La Princesa |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University Hospital Schleswig-Holstein |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University Hospitals Seidman Cancer Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University Medical Center Hamburg-Eppendorf |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Adelaide |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Bologna |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of British Columbia |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of British Columbia |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of California, Davis |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of California, San Francisco |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Franche-Comté |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Lugano |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Melbourne |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Miami |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Milan |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Minnesota |
| Department | Minnesota NMR Center |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Minnesota |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Montreal |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Paris-Saclay |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Pennsylvania |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Port Harcourt Teaching Hospital |
| Country | Nigeria |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of South Florida |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Sydney |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Texas |
| Department | M. D. Anderson Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Toronto |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Washington |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | University of Zurich |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Vall d'Hebron Institute of Oncology |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Walsall College |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
| Organisation | Yokohama City University Medical Centre |
| Country | Japan |
| Sector | Hospitals |
| PI Contribution | Writing, reviewing and editing the manuscript |
| Collaborator Contribution | Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration |
| Impact | https://doi.org/10.1016/j.ejca.2023.02.018 |
| Start Year | 2022 |
| Description | Multivariate Meta-analysis Using IPD (Chapter 13). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Co-authored the chapter |
| Collaborator Contribution | Co-authored the chapter. One partner led writing the chapter and was co-editor of book |
| Impact | 1 book chapter (Chapter 13) |
| Start Year | 2015 |
| Description | Multivariate Meta-analysis Using IPD (Chapter 13). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | Keele University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Co-authored the chapter |
| Collaborator Contribution | Co-authored the chapter. One partner led writing the chapter and was co-editor of book |
| Impact | 1 book chapter (Chapter 13) |
| Start Year | 2015 |
| Description | Preoperative prognostic factors for 5-year survival following pulmonary metastasectomy from colorectal cancer |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Conceptualization; Formal analysis; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Writing-review & editing |
| Collaborator Contribution | Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Software; Writing-original draft; Writing-review & editing. |
| Impact | Protocol: PROSPERO (CRD42021247133) Publication: https://doi.org/10.1093/ejcts/ezad059 |
| Start Year | 2021 |
| Description | Preoperative prognostic factors for 5-year survival following pulmonary metastasectomy from colorectal cancer |
| Organisation | Hillingdon Hospital, Uxbridge |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Conceptualization; Formal analysis; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Writing-review & editing |
| Collaborator Contribution | Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Software; Writing-original draft; Writing-review & editing. |
| Impact | Protocol: PROSPERO (CRD42021247133) Publication: https://doi.org/10.1093/ejcts/ezad059 |
| Start Year | 2021 |
| Description | Preoperative prognostic factors for 5-year survival following pulmonary metastasectomy from colorectal cancer |
| Organisation | Royal Victoria Hospital, Belfast |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Conceptualization; Formal analysis; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Writing-review & editing |
| Collaborator Contribution | Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Software; Writing-original draft; Writing-review & editing. |
| Impact | Protocol: PROSPERO (CRD42021247133) Publication: https://doi.org/10.1093/ejcts/ezad059 |
| Start Year | 2021 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | Albert Ludwig University of Freiburg |
| Department | Faculty of Medicine |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | Li Ka Shing Foundation |
| Country | Hong Kong |
| Sector | Charity/Non Profit |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | University of Bern |
| Department | Institute of Social and Preventive Medicine |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | University of Ioannina |
| Country | Greece |
| Sector | Academic/University |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | University of Paris - Descartes |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | Aix-Marseille University |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | Christus Health |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | Dana-Farber Cancer Institute |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | Duke University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | Erasmus MC |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | Fred Hutchinson Cancer Research Center (FHCRC) |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | Johns Hopkins University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | Memorial Sloan Kettering Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | Northwestern University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | Royal Marsden NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | University of Adelaide |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | University of Hasselt |
| Department | International Drug Development Institute |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Organisation | University of Kyoto |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Collaborator Contribution | Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript |
| Impact | Publication; https://doi.org/10.1200/JCO.23.01535 |
| Start Year | 2020 |
| Description | Rationale for Embarking on an IPD Meta-analysis Project (Chapter 2). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | Keele University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Led writing of chapter. Co-editor of book |
| Collaborator Contribution | Co-authored the chapter, two partners co-editors of book |
| Impact | 1 book chapter (Chapter 2) |
| Start Year | 2015 |
| Description | Rationale for Embarking on an IPD Meta-analysis Project (Chapter 2). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | Queen's University Belfast |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Led writing of chapter. Co-editor of book |
| Collaborator Contribution | Co-authored the chapter, two partners co-editors of book |
| Impact | 1 book chapter (Chapter 2) |
| Start Year | 2015 |
| Description | Rationale for Embarking on an IPD Meta-analysis Project (Chapter 2). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | University of Liverpool |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Led writing of chapter. Co-editor of book |
| Collaborator Contribution | Co-authored the chapter, two partners co-editors of book |
| Impact | 1 book chapter (Chapter 2) |
| Start Year | 2015 |
| Description | Rationale for Embarking on an IPD Meta-analysis Project (Chapter 2). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | University of York |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Led writing of chapter. Co-editor of book |
| Collaborator Contribution | Co-authored the chapter, two partners co-editors of book |
| Impact | 1 book chapter (Chapter 2) |
| Start Year | 2015 |
| Description | ReducIng Self-harm in Adolescents: Individual Participant Data meta-analysis |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of Steering Committee. Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | I protocol (http://dx.doi.org/10.1136/bmjopen-2021-049255) and 1 SAP. |
| Start Year | 2019 |
| Description | ReducIng Self-harm in Adolescents: Individual Participant Data meta-analysis |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of Steering Committee. Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | I protocol (http://dx.doi.org/10.1136/bmjopen-2021-049255) and 1 SAP. |
| Start Year | 2019 |
| Description | ReducIng Self-harm in Adolescents: Individual Participant Data meta-analysis |
| Organisation | University of Leeds |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of Steering Committee. Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | I protocol (http://dx.doi.org/10.1136/bmjopen-2021-049255) and 1 SAP. |
| Start Year | 2019 |
| Description | SMART-IPD Group |
| Organisation | Queen Mary University of London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Meta-analysis methodology expertise |
| Collaborator Contribution | Meta-analysis methodology expertise |
| Impact | International launch meeting held (2024), more planned 2025. |
| Start Year | 2024 |
| Description | SMART-IPD Group |
| Organisation | Queen's University Belfast |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Meta-analysis methodology expertise |
| Collaborator Contribution | Meta-analysis methodology expertise |
| Impact | International launch meeting held (2024), more planned 2025. |
| Start Year | 2024 |
| Description | SMART-IPD Group |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Meta-analysis methodology expertise |
| Collaborator Contribution | Meta-analysis methodology expertise |
| Impact | International launch meeting held (2024), more planned 2025. |
| Start Year | 2024 |
| Description | SMART-IPD Group |
| Organisation | University of Sydney |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Meta-analysis methodology expertise |
| Collaborator Contribution | Meta-analysis methodology expertise |
| Impact | International launch meeting held (2024), more planned 2025. |
| Start Year | 2024 |
| Description | SMART-IPD Group |
| Organisation | University of York |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Meta-analysis methodology expertise |
| Collaborator Contribution | Meta-analysis methodology expertise |
| Impact | International launch meeting held (2024), more planned 2025. |
| Start Year | 2024 |
| Description | Sharing individual participant data: through a systematic reviewer lens |
| Organisation | University of York |
| Department | Centre for Reviews and Dissemination (CRD) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Conceived the idea for the article and drafted the manuscript, approved the final manuscript. |
| Collaborator Contribution | Input into the manuscript and approved the final manuscript |
| Impact | 1 manuscript [doi.org/10.1186/s13063-021-05787-4] |
| Start Year | 2021 |
| Description | The Two-stage Approach to IPD Meta-analysis (Chapter 5). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Co-author of the chapter |
| Collaborator Contribution | Co-authors of the chapter. One partner led writing the chapter and co-editor of book |
| Impact | 1 book chapter (Chapter 5) |
| Start Year | 2015 |
| Description | The Two-stage Approach to IPD Meta-analysis (Chapter 5). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | Keele University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Co-author of the chapter |
| Collaborator Contribution | Co-authors of the chapter. One partner led writing the chapter and co-editor of book |
| Impact | 1 book chapter (Chapter 5) |
| Start Year | 2015 |
| Description | The Two-stage Approach to IPD Meta-analysis (Chapter 5). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | University Medical Center Utrecht (UMC) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Co-author of the chapter |
| Collaborator Contribution | Co-authors of the chapter. One partner led writing the chapter and co-editor of book |
| Impact | 1 book chapter (Chapter 5) |
| Start Year | 2015 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | Camden and Islington NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of California |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of Exeter |
| Department | College of Medicine and Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of Exeter |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of Pennsylvania |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of York |
| Department | Department of Health Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | Vanderbilt University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | Use of multiple covariates in assessing treatment-effect modifiers: A methodological review of individual participant data meta-analyses |
| Organisation | Queen Mary University of London |
| Department | Barts and The London School of Medicine and Dentistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Conceptualization; formal analysis; investigation; supervision; writing - original draft; Writing - review and editing. |
| Collaborator Contribution | Investigation; resources; supervision; writing - review and editing |
| Impact | Protocol: PROSPERO CRD42019126768 Publications: https://doi.org/10.1002/jrsm.1674; 10.1016/j.jclinepi.2023.04.014; 10.1016/j.jclinepi.2023.04.013 |
| Start Year | 2021 |
| Description | Use of multiple covariates in assessing treatment-effect modifiers: A methodological review of individual participant data meta-analyses |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Conceptualization; formal analysis; investigation; supervision; writing - original draft; Writing - review and editing. |
| Collaborator Contribution | Investigation; resources; supervision; writing - review and editing |
| Impact | Protocol: PROSPERO CRD42019126768 Publications: https://doi.org/10.1002/jrsm.1674; 10.1016/j.jclinepi.2023.04.014; 10.1016/j.jclinepi.2023.04.013 |
| Start Year | 2021 |
| Description | Using individual participant data to improve network meta-analysis projects |
| Organisation | Keele University |
| Department | School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Members of the research team provided feedback and advice during the project, and commented on the final manuscript |
| Collaborator Contribution | Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript |
| Impact | 1 paper (PMID: 35948411) |
| Start Year | 2022 |
| Description | Using individual participant data to improve network meta-analysis projects |
| Organisation | University of Bern |
| Department | Institute of Social and Preventive Medicine |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Members of the research team provided feedback and advice during the project, and commented on the final manuscript |
| Collaborator Contribution | Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript |
| Impact | 1 paper (PMID: 35948411) |
| Start Year | 2022 |
| Description | Using individual participant data to improve network meta-analysis projects |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Members of the research team provided feedback and advice during the project, and commented on the final manuscript |
| Collaborator Contribution | Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript |
| Impact | 1 paper (PMID: 35948411) |
| Start Year | 2022 |
| Description | Using individual participant data to improve network meta-analysis projects |
| Organisation | University of Liverpool |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Members of the research team provided feedback and advice during the project, and commented on the final manuscript |
| Collaborator Contribution | Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript |
| Impact | 1 paper (PMID: 35948411) |
| Start Year | 2022 |
| Description | Using individual participant data to improve network meta-analysis projects |
| Organisation | University of York |
| Department | Centre for Reviews and Dissemination (CRD) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Members of the research team provided feedback and advice during the project, and commented on the final manuscript |
| Collaborator Contribution | Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript |
| Impact | 1 paper (PMID: 35948411) |
| Start Year | 2022 |
| Description | Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD) |
| Organisation | University of British Columbia |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Developed protocol and analysis plan; collected and checked the individual participant data; carried out analysis; interpreted results and wrote the abstract |
| Collaborator Contribution | Supplied the individual participant data, reviewed results and commented on the abstract |
| Impact | two protocols (PROSPERO CRD42023431331; CRD4202540066) one conference abstract / presentation (oral) (doi.org/10.1200/JCO.2025.43.5_suppl.20) |
| Start Year | 2024 |
| Description | Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD) |
| Organisation | University of Utah |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Developed protocol and analysis plan; collected and checked the individual participant data; carried out analysis; interpreted results and wrote the abstract |
| Collaborator Contribution | Supplied the individual participant data, reviewed results and commented on the abstract |
| Impact | two protocols (PROSPERO CRD42023431331; CRD4202540066) one conference abstract / presentation (oral) (doi.org/10.1200/JCO.2025.43.5_suppl.20) |
| Start Year | 2024 |
| Description | Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? |
| Organisation | Catholic University of Louvain |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report. |
| Collaborator Contribution | Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission |
| Impact | Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9 |
| Start Year | 2021 |
| Description | Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? |
| Organisation | Dana-Farber Cancer Institute |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report. |
| Collaborator Contribution | Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission |
| Impact | Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9 |
| Start Year | 2021 |
| Description | Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? |
| Organisation | Institute of Cancer Research UK |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report. |
| Collaborator Contribution | Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission |
| Impact | Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9 |
| Start Year | 2021 |
| Description | Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? |
| Organisation | Paoli-Calmettes Institute |
| Country | France |
| Sector | Hospitals |
| PI Contribution | Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report. |
| Collaborator Contribution | Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission |
| Impact | Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9 |
| Start Year | 2021 |
| Description | Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? |
| Organisation | Salford Royal Hospital |
| Department | Christie at Salford Royal Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report. |
| Collaborator Contribution | Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission |
| Impact | Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9 |
| Start Year | 2021 |
| Description | Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? |
| Organisation | University of Adelaide |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report. |
| Collaborator Contribution | Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission |
| Impact | Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9 |
| Start Year | 2021 |
| Description | Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? |
| Organisation | University of Paris-Saclay |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report. |
| Collaborator Contribution | Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission |
| Impact | Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9 |
| Start Year | 2021 |
| Description | Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? |
| Organisation | University of Wisconsin-Madison |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report. |
| Collaborator Contribution | Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission |
| Impact | Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9 |
| Start Year | 2021 |
| Title | metafloat |
| Description | metafloat: estimation of covariate interactions and subgroup-specific treatment effects in meta-analysis |
| Type Of Technology | Software |
| Year Produced | 2023 |
| Open Source License? | Yes |
| Impact | The "metafloat" package was developed to implement the methodology described in Godolphin et al (Res Syn Meth 2023, https://doi.org/10.1002/jrsm.1590). As a result of dissemination activity surrounding this paper, the authors have received communication from users of the software. Furthermore, elements of the software have been used to create figures within notable recent papers including Shankar-Hari et al (JAMA 2021, https://doi.org/10.1001/jama.2021.11330) and Vale et al (Lancet Oncol 2023, https://doi.org/10.1016/S1470-2045(23)00230-9). |
| URL | https://github.com/UCL/metafloat |
| Title | metan update |
| Description | Update of metan: fixed and random-effects meta-analysis |
| Type Of Technology | Software |
| Year Produced | 2024 |
| Open Source License? | Yes |
| Impact | The "metan" package was originally developed in 1998 by experts in the field, with major updates in 2010 and 2020. As of 2020, it is maintained by David Fisher at MRC Clinical Trials Unit at UCL, with the most recent update in September 2023. Although Stata now has built-in meta-analysis functionality, there remains a need for a comprehensive, adaptable user-written package. In the 12 months between July 2022 and June 2023, "metan" was downloaded on average 3,800 times per month. |
| URL | https://ideas.repec.org/c/boc/bocode/s456798.html |
| Title | mvmeta update |
| Description | Update of mvmeta: multivariate meta-analysis |
| Type Of Technology | Software |
| Year Produced | 2022 |
| Open Source License? | Yes |
| Impact | The original software has been used to improve precision and reduce bias in several published meta-analysis, and is an essential part of the widely used "network" package for performing network meta-analysis in Stata. The update has no impact as yet. |
| URL | https://ideas.repec.org/c/boc/bocode/s456970.html |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Submitted a nomination to the Cochrane Reward Prize to demonstrate how a collaborative and prospective approach to meta-analysis can produce timely, reliable and thorough aggregate data meta-analysis in COVID 19, thereby reducing research waste. The submission made it to the second round of judging. |
| Year(s) Of Engagement Activity | 2021 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A series of Tweets directed at different audiences e.g. systematic reviewers; clinicians, and making use of collaborators influential on twitter. News story on MRC CTU@ UCL website and STOPCAPM1 website |
| Year(s) Of Engagement Activity | 2021 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Invited to contribute to Cochrane's response to the WHO consultation 'World Health Assembly Resolution on strengthening clinical trials'. Focussing on how FAME Framework can help to reduce research waste. |
| Year(s) Of Engagement Activity | 2022 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Title: How can a framework for prospective, adaptive meta-analysis (FAME) improve the quality of Cochrane reviews? Presenter: Jayne Tierney Cochrane Colloguium 2023, London Oral Presentations - Wednesday 6th September - 15:05-15:25 |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://events.cochrane.org/colloquium-2023/schedule |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | The MiM meeting is a seminar series bringing together researchers who work in meta-analysis methodology. Presenting this work to this audience was an opportunity to promote the value of the approach taken to this review and the benefits it brings. It sparked interest and discussion among those keen to adapt their own approach to meta-analysis in similar ways |
| Year(s) Of Engagement Activity | 2021 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Title: How can the framework for prospective, adaptive meta-analysis (FAME) be used to improve the quality of Cochrane reviews? Presentation given by Jayne Tierney for the Cochrane Methods Support Unit, aimed at Cochrane reviewers. Aug 2023 |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://training.cochrane.org/resource/msu-web-clinic-august-2023 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation at meeting of Methodologists to describe the considerable dissemination activities that took place around the publication of the FAME manuscript |
| Year(s) Of Engagement Activity | 2021 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A short questionnaire was emailed to a range of Systematic Review experts, asking them to read the manuscript and then respond as to whether they liked it or not and why, and whether they thought they would use the methods or not and why. This helped identify barriers and concerns that will influence future engagement and research on FAME |
| Year(s) Of Engagement Activity | 2021 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Response to an opinion piece (published in Nature) critical of aggregate data meta-analysis for COVID 19, to demonstrate how a collaborative and prospective approach to meta-analysis can produce timely, reliable and thorough aggregate data meta-analysis in COVID 19. |
| Year(s) Of Engagement Activity | 2021 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | JT and SB invited to host a live webinar for Cochrane Methods Support Unit. 'How can the framework for prospective, adaptive meta-analysis (FAME) be used to improve the quality of Cochrane reviews?' (9 March 2023) |
| Year(s) Of Engagement Activity | 2023 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Twitter posts (story and thread); News story on MRC CTU @ UCL website |
| Year(s) Of Engagement Activity | 2022 |
| Description | Annals of Internal Medicine Video Summary - Anticoagulation Among Patients Hospitalized for COVID-19 |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | On publication of the manuscript, Annals of Interna Medicine produced an animation of results, aimed at clinicians |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.acpjournals.org/doi/full/10.7326/ANNALS-24-03257-VS |
| Description | Anticoagulation Among Patients Hospitalized for COVID-19: A Systematic Review and Prospective Meta-analysis |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Results presented to the WHO Covid therapeutics guideline development group. WHO Guideline Development Group (GDG) is made up of an expert panel of global experts, frontline providers and patient partners developing transparent and trustworthy quality COVID-19 clinical practice guidelines. Findings will be included in the upcoming guideline update (due to be published Spring 2025) |
| Year(s) Of Engagement Activity | 2024 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The world evidence based healthcare day 2021 was a call to the global evidence community to share their experiences, expertise and stories on infodemic management in the wake of the COVID pandemic. It is a global initiative that aims to raise awareness of the need for better evidence to inform healthcare policy, practice and decision making in order to improve health outcomes globally. It also provides an opportunity to participate in debate and to celebrate the impact of individuals and organisations worldwide, recognising the work of dedicated researchers, policymakers and health professionals in improving health outcomes. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The MiM meeting is a seminar series bringing together researchers who work in meta-analysis methodology. Presenting this work to this audience was an opportunity to promote the value of the approach taken to this review and the benefits it brings. It sparked interest and discussion among those keen to adapt their own approach to meta-analysis in similar ways |
| Year(s) Of Engagement Activity | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Presented the preliminary results of the IL-6 meta-analysis to the WHO Guideline development group and answered questions and queries on the methods and results. This is the group responsible for deciding whether new WHO guidelines will recommend a treatment or not based on the evidence available to them |
| Year(s) Of Engagement Activity | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | A press release to coincide with the publication of this work and the accompanying WHO Guideline was written and disseminated in conjunction with Kings College London, University of Bristol, UCL and WHO teams. It was picked up in a number of media outlets, including Bloomberg, Reuters, Daily Mail, NBC News, AFP, and dozens of international titles |
| Year(s) Of Engagement Activity | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Used a series of tweet to promote the key messages of the review as well as aspects of the methodology used to highlight the value in the approach. The tweets were retweeted, and quoted by more than 60 news outlets. The Altmetric score is 871, putting the article in the top 5% of all research outputs, largely driven by activity on Twitter. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented the findings of the IL6 review to the MRCCTU staff as part of the lunchtime seminar series, and answered queries both about the methods used, results and their impact and meaning. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This summarised the process and merits of the approach taken to this piece of research, the value of collaboration and how extensive and efficient the process was. It was included on the MRC CTU website and promoted on Twitter |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.mrcctu.ucl.ac.uk/our-research/methodology/meta-analysis/blog-interlukin-6-antagonists-im... |
| Description | Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Tweets were written and sent publicising the findings of this paper |
| Year(s) Of Engagement Activity | 2022 |
| Description | Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Pre-publication manuscript was shared with Public Health England. as Tocilizumab, an interleukin-6 receptor antagonist that was shown to reduce mortality for patients hospitalised with COVID-19 and stores in England were running low. The paper provided evidence that Sarilumab (an alternative interleukin-6 receptor antagonist) had similar mortality benefits |
| Year(s) Of Engagement Activity | 2022 |
| Description | Biarritz NMA course |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A 3-day course on network meta-analysis was delivered to 30 participants, mostly from Europe. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.cer-methods.com/2021/12/09/nmacourse/ |
| Description | COCROACH Collaboration: prospective, individual participant data meta-analysis of randomised trials |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Relating to publication of Al Shai Salman et al (doi: 10.1016/S1474-4422(23)00315-0) Title: THE EFFECTS OF LONG-TERM ORAL ANTICOAGULANT AGENTS FOR ATRIAL FIBRILLATION (AF) AFTER INTRACRANIAL HAEMORRHAGE (ICH): PROSPECTIVE INDIVIDUAL PARTICIPANT DATA META-ANALYSIS (IPDMA) OF RANDOMISED CONTROLLED TRIALS Presenter: Rustam Al Shai Salman Conference: 15th World Stroke Congress 2023, Toronto |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://cslide.ctimeetingtech.com/wsc23/attendee/person/94 |
| Description | COCROACH Collaboration: prospective, individual participant data meta-analysis of randomised trials |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Relating to publication of Al-Shahi Salman R (doi:10.1016/S1474-4422(23)00315-0) Podcast for the Lancet Neurology by first Author of paper Rustam Al-Shahi Salman |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.buzzsprout.com/1391383/13968688 |
| Description | Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Thread of short posts taking readers through the paper step by step. This series of posts was posted both on Twitter and Mastodon |
| Year(s) Of Engagement Activity | 2023 |
| Description | Editorial - Anticoagulation for COVID-19: Seeking Clarity and Finding Yet More Gray |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | For publication of manuscript, Annals of Internal Medicine commissioned an Editorial to accompany the publication |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.acpjournals.org/doi/full/10.7326/ANNALS-24-03244 |
| Description | Ensuring more people with advanced prostate cancer receive effective treatments |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | At the Prostate Cancer UK Research Conference 'From Ideas to Innovation' (17-18 April 2024), Dr Vale presented ongoing work from our STOPCAP Collaboration 'Ensuring more people with advanced prostate cancer receive effective treatments' |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://prostatecanceruk.org/research/for-researchers/from-ideas-to-innovation |
| Description | Estimating interactions and subgroup-specific treatment effects in meta-analysis without aggregation bias: A within-trial framework |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Conference paper presentation at the Society for Clinical Trials Annual Meeting for both an in-person and virtual audience. The talk and paper won the Thomas Chalmer's Award from the Society |
| Year(s) Of Engagement Activity | 2022 |
| Description | Estimating interactions and subgroup-specific treatment effects in meta-analysis without aggregation bias: A within-trial framework |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | After engagement with the PPI members, authors wrote (with PPI members support) content for a news story hosted the MRC CTU website and an associated twitter thread that was widely shared. After this content was live, the authors have since been contacted by two separate researchers asking for clarification on the method and advice implementing the method in their own studies |
| Year(s) Of Engagement Activity | 2022 |
| Description | Estimating interactions and subgroup-specific treatment effects in meta-analysis without aggregation bias: A within-trial framework |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Two of the authors (PG, DF) engaged with two patient and public representatives to help improve dissemination of the methodology and reach a wider audience. The PPI members contributed to writing and editing content to be shared on social platforms. |
| Year(s) Of Engagement Activity | 2022 |
| Description | How can we use IPD to work out who benefits most from treatments? (UCL-USyd Ignition Grant - Sydney) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | As part of the UCL-USyd Ignition Grant (P Godolphin / AL Seidler): Towards more trustworthy evidence for all - developing a framework for best practice IPD meta-analysis. PG presented 'How can we use IPD to work out who benefits most from treatments?' at the University of University of Sydney, Clinical Trials Centre Symposium in April 2024 |
| Year(s) Of Engagement Activity | 2024 |
| Description | ICTMC: Involving trialists for better evidence synthesis: Lessons from a case study in COVID-19 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dr Vale presented 'Involving trialists for better evidence synthesis: Lessons from a case study in COVID-19' (oral) at The 7th International Clinical Trials Methodology Conference (Edinburgh 20 September to 3rd October 2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | ICTMC: Involving trialists in evidence synthesis: benefits for trials and meta-analyses |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prof Tierney presented 'Involving trialists in evidence synthesis: benefits for trials and meta-analyses' (poster) at The 7th International Clinical Trials Methodology Conference (Edinburgh 20 September to 3rd October 2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | Identifying which therapies are best for which people advanced prostate cancer |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | At the Prostate Cancer UK Research Conference 'From Ideas to Innovation' (17-18 April 2024), Prof Tierney presented ongoing work from our STOPCAP Collaboration 'Identifying which therapies are best for which people advanced prostate cancer' |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://prostatecanceruk.org/research/for-researchers/from-ideas-to-innovation |
| Description | Individual Participant Data Meta-analysis: A Handbook for Healthcare Research |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Contributed to website aimed at promoting the book |
| Year(s) Of Engagement Activity | 2021,2022 |
| URL | https://www.ipdma.co.uk/textbook |
| Description | Individual participant data meta-analysis: A handbook for healthcare research |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Tweets announcing publication through the MRC CTU Twitter account |
| Year(s) Of Engagement Activity | 2021 |
| Description | Interactions in MA: Subgroup effect estimates consistent with the "deft" interaction (common-effects) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Title: Reliably estimating interactions and subgroup effects in aggregate data meta-analysis Presenter: Peter Godolphin Cochrane Colloquium 2023, London (https://events.cochrane.org/colloquium-2023/schedule) Oral Presentations, Tuesday, 5 September 2023, 11:25 - 11:45 This presentation won 2023 Thomas C Chalmers Award - Best Long Oral |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://community.cochrane.org/news/winner-2023-thomas-c-chalmers-award-best-long-oral-presentation-... |
| Description | Interactions in MA: Subgroup effect estimates consistent with the "deft" interaction (common-effects) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Relating to publication: Godolphin et al (doi: 10.1002/jrsm.1590.) Title: Identifying who benefits most from treatments: estimating interactions and subgroup effects in aggregate data meta-analysis [January 2024] Presenter: Peter Godolphin Cochrane Learning Events - Methods - Meta-analysis and other statistical methods (January 2024). Cochrane Learning Live is a series of online learning events open to everyone |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://training.cochrane.org/resource/estimating-interactions-and-subgroup-effects-in-aggregate-dat... |
| Description | Involving trialists in evidence synthesis: Benefits for trials and meta-analysis |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prof Tierney presented 'Involving trialists in evidence synthesis: Benefits for trials and meta-analysis' at a UK Clinical Research Collaboration (UKCRC) webinar (Dec 2024). This presentation outlines the principles of FAME methodology and how it can benefit those carrying out systematic reviews. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.ukcrc.org/ |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | A blog post from the co-author discussing the research in the context of her personal experience as a pregnant woman at risk of iron deficiency anaemia. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.qmul.ac.uk/media/news/2021/smd/pregnant-women-need-more-information-and-options-for-trea... |
| Description | Maximising the value of trials for evidence synthesis: From prostate cancer to the pandemic |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prof Tierney presented 'Maximising the value of trials for evidence synthesis: From prostate cancer to the pandemic' at the Wolfson Institute of Population Health, Queen Mary University, London. This presentation outlines the principles of FAME methodology and how it can benefit those carrying out systematic reviews. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.qmul.ac.uk/wiph/ |
| Description | Meta-analyses based on summary data can provide timely, thorough and reliable evidence: don't dismiss them yet |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A twitter thread summarising the rationale for this work and the key messages was written by one of the authors. To date, this has had over 300 engagements. The journal, with over 300K followers also widely shared the work and created an infographic with a quote from the paper that has been retweeted widely. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Meta-analyses based on summary data can provide timely, thorough and reliable evidence: don't dismiss them yet |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The work in this paper was presented during the national 2022 'Meta-Analysis in Medicine' meeting (that had invited international colleagues) of statisticians who specialise in meta-analysis, including some PhD students. The talk sparked numerous questions from the audience. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Predicting individualised treatment effects whilst avoiding aggregation bias (UCL-USyd Ignition Grant - Birmingham) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | As part of the UCL-USyd Ignition Grant (P Godolphin / AL Seidler): Towards more trustworthy evidence for all - developing a framework for best practice IPD meta-analysis. PG presented 'Predicting individualised treatment effects whilst avoiding aggregation bias' at the University of Birmingham Biostatistics, Evidence Synthesis, Test Evaluation and Prediction Models Seminar in Sept 2024 |
| Year(s) Of Engagement Activity | 2024 |
| Description | Presentation: 'metan: a Stata package for performing aggregate-data meta-analysis' |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | The updated version of the STATA program METAN was presented at the UCL-wide workshop "Writing methodological software for statistical applications in health". Presentation entitled "metan: a Stata package for performing aggregate-data meta-analysis" |
| Year(s) Of Engagement Activity | 2022 |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Relating to publication of: Halabi S et al. Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2024 Jan 5:JCO2301535. doi: 10.1200/JCO.23.01535. Epub ahead of print. PMID: 38181323. On publication, news story on MRC CTU at UCL website (www.mrcctu@ucl.ac.uk) and www.STOPCAPM1.org https://www.mrcctu.ucl.ac.uk/news/news-stories/2024/february/new-prostate-cancer-treatments-could-reach-men-sooner/ http://www.stopcapm1.org/news/news-stories/2024/february/new-prostate-cancer-treatments-could-reach-men-sooner/ |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.mrcctu.ucl.ac.uk/news/news-stories/2024/february/new-prostate-cancer-treatments-could-re... |
| Description | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Relating to publication of Halabi S et al. (doi: 10.1200/JCO.23.01535) On publication, a press release from the Prostate Cancer Foundation (PCF), USA. Title: New Prostate Cancer Foundation-Funded Research To Speed Up Prostate Cancer Clinical Trials Worldwide The press release led to the following news outlets reporting this work MSN; Yahoo; Morningstar; PR Newswire; OncLive; MedicalXpress; Drugs.com and ProfitQuotes |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.pcf.org/news/new-prostate-cancer-foundation-funded-research-to-speed-up-prostate-cancer-... |
| Description | STOPCAP: Prognostic Models & Surrogacy - Assessing Intermediate Clinical Endpoints (ICE) as potential surrogates for Overall Survival (OS) in Subgroups of men with Metastatic Hormone Sensitive Prostate Cancer' |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prof Halabi presented an update of our worldwide collaboration - STOPCAP - investigating treatments for men with metastatic hormone sensitive prostate cancer. This was at the annual Movember / ICECAP meeting. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://movember.app.box.com/s/zh11vdh2htvdjqkbmbr2ex18k4veyk4l |
| Description | STOPCAP: Treatment Effect - IPD meta-analyses to help determine which men with mHSPC should receive second-generation anti-androgens, docetaxel or their combination |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prof Tierney presented an update of our worldwide collaboration - STOPCAP - investigating treatments for men with metastatic hormone sensitive prostate cancer. This was at the annual Movember / ICECAP meeting. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://movember.app.box.com/s/q3n6fdknt1u13lcrpwlz5wlul105e45g |
| Description | Sharing individual participant data: through a systematic reviewer lens |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Tweets and new story on MRC CTU @ UCL website |
| Year(s) Of Engagement Activity | 2021 |
| Description | Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: A World Health Organization-coordinated prospective meta-analysis of randomised trials |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Title: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: A World Health Organization-coordinated prospective meta-analysis of randomised trials Author: Mikhail Kosiborod, MD on behalf of The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Conference: European Society of Cardiologists Congress, August 28th, 2023 Full paper has been submitted to a journal |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://esc365.escardio.org/home |
| Description | Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: prospective meta-analysis of randomised trials. |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Results presented to the WHO Covid therapeutics guideline development group. WHO Guideline Development Group (GDG) is made up of an expert panel of global experts, frontline providers and patient partners developing transparent and trustworthy quality COVID-19 clinical practice guidelines. Findings will be included in the upcoming guideline update (due to be published Spring 2025) |
| Year(s) Of Engagement Activity | 2024 |
| Description | State of play in individual participant data meta-analyses of randomised trials (UCL-USyd Ignition Grant - Birmingham) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | As part of the UCL-USyd Ignition Grant (P Godolphin / AL Seidler): Towards more trustworthy evidence for all - developing a framework for best practice IPD meta-analysis. PG & ALS presented 'State of play in individual participant data meta-analyses of randomised trials ' at the University of Birmingham Biostatistics, Evidence Synthesis, Test Evaluation and Prediction Models Seminar in Sept 2024 |
| Year(s) Of Engagement Activity | 2024 |
| Description | Two-stage or not two-stage? That is the question for IPD meta-analysis projects |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Relating to the publication of Riley et al: (doi: 10.1002/jrsm.1661) Engagement on twitter/x by first author (Richard Riley) https://x.com/Richard_D_Riley/status/1693978578881302791 https://x.com/Richard_D_Riley/status/1758126377599950898 https://x.com/Richard_D_Riley/status/1711417266275807496 |
| Year(s) Of Engagement Activity | 2023 |
| Description | Use of multiple covariates in assessing treatment-effect modifiers: A methodological review of individual participant data meta-analyses |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Relating to: Godolphin PJ et al (doi:10.1002/jrsm.1674); Marlin N et al (doi: 10.1016/j.jclinepi.2023.04.014) and Marlin N et al. (doi: 10.1016/j.jclinepi.2023.04.013) Twitter posts to draw attention to the publications by Peter Godolphin https://twitter.com/petegodolphin/status/1671902761523240961 https://twitter.com/MRCCTU/status/1712479530122969234 |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://twitter.com/petegodolphin/status/1671902761523240961 |
| Description | Use of multiple covariates in assessing treatment-effect modifiers: A methodological review of individual participant data meta-analyses |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Relating to: Godolphin PJ et al (doi:10.1002/jrsm.1674); Marlin N et al (doi: 10.1016/j.jclinepi.2023.04.014) and Marlin N et al. (doi: 10.1016/j.jclinepi.2023.04.013) Presentation Title: Estimation of treatment-covariate interactions in individual participant data meta-analyses of randomised trials: What questions are we addressing? Event: Meta-analysis in Medicine (MiM), 28.11.2023 Audience: statisticians/methodologists working in meta-analysis |
| Year(s) Of Engagement Activity | 2023 |
| Description | Use of multiple covariates in assessing treatment-effect modifiers: A methodological review of individual participant data meta-analyses |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Relating to: Godolphin PJ et al (doi:10.1002/jrsm.1674); Marlin N et al (doi: 10.1016/j.jclinepi.2023.04.014) and Marlin N et al. (doi: 10.1016/j.jclinepi.2023.04.013) Presentation Title: Use of multiple covariates in assessing treatment-effect modifiers: A methodological review of IPD meta-analyses Event: Society for Research Synthesis Methodology, 2023 Audience: statisticians/methodologists working in meta-analysis |
| Year(s) Of Engagement Activity | 2023 |
| Description | Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD) (MRC CTU Website) |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | News story on www.mrcctu.acu.ac.uk website about presentation of individual participant data meta-analysis results at American Society of Clinical Oncology Genitourinary (ASCO GU) Meeting in San Francisco, USA (13 February 2025) |
| Year(s) Of Engagement Activity | 2025 |
| URL | https://www.mrcctu.ucl.ac.uk/news/news-stories/2025/february/stopcap-study-finds-that-most-men-with-... |
| Description | Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD). (STOPCAP Website) |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | News story on www.stopcapm1.org website about presentation of individual participant data meta-analysis results at American Society of Clinical Oncology Genitourinary (ASCO GU) Meeting in San Francisco, USA (13 February 2025) |
| Year(s) Of Engagement Activity | 2025 |
| URL | https://www.stopcapm1.org/news/news-stories/2025/february/most-men-with-advanced-prostate-cancer-ben... |
| Description | Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trial |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Relating to publication of: Vale CL et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 2023 Jul;24(7):783-797. doi: 10.1016/S1470-2045(23)00230-9. PMID: 37414011. Briefing Paper; July 2023, Issue 34. Published on MRC CTU at UCL website Which people with metastatic prostate cancer benefit most from docetaxel? |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.mrcctu.ucl.ac.uk/media/2405/docetaxel-m1-meta-analysis-briefing-june23_v3.pdf |
| Description | Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Relating to publication of: Vale CL et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 2023 Jul;24(7):783-797. doi: 10.1016/S1470-2045(23)00230-9. PMID: 37414011. On publication there were a number of engagement activities including tweets from the Unit Twitter account, News story on Unit website (www.mrcctu.ucl.ac.uk) and www.STOPCAPM1.org website http://www.stopcapm1.org/news/news-stories/2023/july/latest-stopcap-m1-results-published/ https://www.mrcctu.ucl.ac.uk/news/news-stories/2023/july/which-people-with-metastatic-prostate-cancer-benefit-most-from-upfront-docetaxel/ |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.mrcctu.ucl.ac.uk/news/news-stories/2023/july/which-people-with-metastatic-prostate-cance... |
| Description | metan: Stata package for aggregate-data MA |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Title: metan: a comprehensive update to the popular user-written meta-analysis package for Stata Presenter: David Fisher Cochrane Colloquium 2023; London Poster presentation, Tuesday, 5 September 2023, 12:30 - 14:00 |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://events.cochrane.org/colloquium-2023/schedule |